Unicycive Therapeutics Files 8-K
Ticker: UNCY · Form: 8-K · Filed: Jun 10, 2025 · CIK: 1766140
| Field | Detail |
|---|---|
| Company | Unicycive Therapeutics, Inc. (UNCY) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, financial-reporting, regulatory-filing
TL;DR
Unicycive Therapeutics filed an 8-K on June 10, 2025, for 'Other Events' and financial exhibits.
AI Summary
On June 10, 2025, Unicycive Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant business occurrences. Specific details regarding the nature of these events or financial statements are not elaborated in the provided text.
Why It Matters
This filing signals to investors that Unicycive Therapeutics has made a significant disclosure or update, potentially impacting its stock value and requiring further investigation into the specific events or financial data presented.
Risk Assessment
Risk Level: medium — An 8-K filing indicates material events, which can introduce volatility and uncertainty for investors, necessitating a review of the disclosed information.
Key Players & Entities
- Unicycive Therapeutics, Inc. (company) — Registrant
- June 10, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40582 (identifier) — Commission File Number
- 81-3638692 (identifier) — IRS Employer Identification No.
- 4300 El Camino Real, Suite 210 (address) — Principal executive offices
- Los Altos, CA 94022 (address) — Principal executive offices
- (650) 351-4495 (phone_number) — Registrant's telephone number
FAQ
What specific 'Other Events' are being reported by Unicycive Therapeutics, Inc. in this 8-K filing?
The provided text for the 8-K filing lists 'Other Events' as an item information category but does not specify the nature of these events.
What is the significance of the 'Financial Statements and Exhibits' being filed?
The filing of 'Financial Statements and Exhibits' suggests that Unicycive Therapeutics, Inc. is providing updated financial information or accompanying documents that are material to investors.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 10, 2025.
What is Unicycive Therapeutics, Inc.'s state of incorporation and principal executive office address?
Unicycive Therapeutics, Inc. is incorporated in Delaware and its principal executive offices are located at 4300 El Camino Real, Suite 210, Los Altos, CA 94022.
What is the Commission File Number and IRS Employer Identification Number for Unicycive Therapeutics, Inc.?
The Commission File Number for Unicycive Therapeutics, Inc. is 001-40582, and its IRS Employer Identification Number is 81-3638692.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 10, 2025 regarding Unicycive Therapeutics, Inc. (UNCY).